Anyone interested in participating in a clinical study should know as much as possible about the study and feel comfortable asking the research team questions about the study and related procedures. Some introductory information is available on this page, but we also encourage you to contact us by Contact Us or reach out to one of the study sites.
If are interested in taking part in the ADAPT study, or you would simply like more information, you can also learn more at www.clinicaltrials.gov.
To participate in this study, you will be asked to read and sign an Informed Consent form. You are encouraged to ask any questions you have about the form, which discusses in detail:
During screening, certain tests will be done to evaluate whether your disease meets the criteria for the study. The screening period can last up to 2 weeks.
You will be randomly assigned to one of two groups: efgartigimod or placebo. The study is blinded, meaning that neither you nor the study team will know which treatment you are receiving. In both groups, you will be able to continue your current treatments for gMGa.
The study will take place over a 6-month period. When the study period is complete, patients in both the efgartigimod and placebo groups may be given the opportunity to receive efgartigimod in a year-long follow-up study.
In addition to receiving treatment with either efgartigimod or the placebo, your visits may include additional tests and procedures, such asb:
There is no cost to enrolled patients for the investigational treatment or for study-specific examinations, procedures, or laboratory services.
This website requires cookies to provide all of its features and uses tracking technologies. For more information, please see the Website Usage Policies page. If you continue to use this site, you agree with the Terms and Conditions.Learn More